Jump Financial LLC Takes $2.51 Million Position in Tarsus Pharmaceuticals, Inc. $TARS

Key Points

• Jump Financial LLC acquired a new position in Tarsus Pharmaceuticals, purchasing approximately 48,800 shares valued at $2.51 million in the first quarter.
• Tarsus Pharmaceuticals has a market cap of $2.48 billion and reported a revenue of $102.66 million for the last quarter, surpassing estimates.
• Several analysts have a consensus rating of "Buy" for Tarsus Pharmaceuticals, with price targets ranging from $51.00 to $84.00, indicating positive market sentiment.

Jump Financial LLC purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 48,800 shares of the company's stock, valued at approximately $2,507,000. Jump Financial LLC owned approximately 0.12% of Tarsus Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. acquired a new position in Tarsus Pharmaceuticals during the 4th quarter worth $44,000. Amalgamated Bank lifted its position in shares of Tarsus Pharmaceuticals by 30.1% during the first quarter. Amalgamated Bank now owns 1,274 shares of the company's stock worth $65,000 after purchasing an additional 295 shares during the last quarter. Quarry LP acquired a new position in Tarsus Pharmaceuticals in the fourth quarter worth about $166,000. AlphaQuest LLC acquired a new stake in Tarsus Pharmaceuticals during the first quarter valued at approximately $189,000. Finally, Bayesian Capital Management LP bought a new position in Tarsus Pharmaceuticals during the 4th quarter worth approximately $228,000. 90.01% of the stock is owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Trading Up 4.0%

Shares of Tarsus Pharmaceuticals stock opened at $58.85 on Wednesday. The business has a fifty day simple moving average of $44.53 and a 200-day simple moving average of $45.86. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $25.82 and a fifty-two week high of $58.95. The firm has a market cap of $2.48 billion, a price-to-earnings ratio of -25.26 and a beta of 0.79. The company has a quick ratio of 5.21, a current ratio of 5.26 and a debt-to-equity ratio of 0.22.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.15). Tarsus Pharmaceuticals had a negative return on equity of 32.36% and a negative net margin of 31.13%.The business had revenue of $102.66 million during the quarter, compared to the consensus estimate of $95.81 million. On average, equities analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on TARS. The Goldman Sachs Group upped their price target on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a research report on Monday, May 5th. HC Wainwright upgraded shares of Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 target price for the company in a research note on Tuesday, May 27th. Oppenheimer began coverage on shares of Tarsus Pharmaceuticals in a report on Monday, June 2nd. They issued an "outperform" rating and a $75.00 price target for the company. Wall Street Zen lowered shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Finally, Guggenheim raised their target price on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $66.67.

Insider Activity

In related news, CEO Bobak R. Azamian sold 6,000 shares of the business's stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $50.00, for a total value of $300,000.00. Following the sale, the chief executive officer directly owned 818,106 shares in the company, valued at $40,905,300. The trade was a 0.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 8.97% of the stock is owned by corporate insiders.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

Want to see what other hedge funds are holding TARS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.